Pediatric Gastroenterology
Meet the immunologists redefining the future of practice, research, and technology! The touchIMMUNOLOGY Future Leaders 2026 have been nominated by the immunology community to recognize the rising stars shaping the future of research and clinical care. These clinicians, researchers and innovators are driving progress across the specialty — from advancing clinical practice to challenging convention and improving patient outcomes.
In this Q&A, touchIMMUNOLOGY Future Leader Dr Karl Mårild reflects on what first drew him to pediatric gastroenterology, the colleagues who shaped his career, and the defining breakthroughs in his research.
Several presentations and abstracts from last month’s European Crohn’s and Colitis Organisation (ECCO) 2026 congress highlighted emerging concepts extending beyond therapeutic efficacy in inflammatory bowel disease (IBD). These included new insights into the gut–brain axis, comparative safety across therapies, artificial intelligence (AI) tools for clinical practice, comorbid metabolic disease and molecular approaches to defining disease remission. Together, these studies illustrate the expanding scope of IBD research and the growing focus on more comprehensive approaches to disease assessment and management.
In a post-hoc analysis of the 100-week data from the EoE KIDS study, long-term treatment with dupilumab was associated with sustained symptom improvement in children with eosinophilic esophagitis (EoE). In this Q&A, Dr Salvatore Oliva (Sapienza University of Rome, Rome, Italy) discusses the study’s findings, the safety profile of dupilumab, and how these results are shaping the treatment landscape for paediatric EoE.
Eosinophilic esophagitis (EoE) is a chronic, often debilitating condition that can significantly impact children’s growth and quality of life. Dupilumab, a fully human monoclonal antibody that inhibits IL-4 and IL-13 signaling, has emerged as a promising treatment option. In this Q&A, Dr Margaret H. Collins, a pathologist at Cincinnati Children’s Hospital, discusses the burden of pediatric EoE, the mechanism of action of dupilumab, and key findings from the phase 3 EoE KIDS trial, which demonstrated meaningful improvements in disease activity and a safety profile consistent with prior studies.
As touchIMMUNOLOGY approaches 5 years of providing education for busy healthcare professionals involved with immune-related conditions, we are looking to the future—and it certainly looks bright! This year, we are celebrating our inaugural touchIMMUNOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform the field in the years to come.
The American College of Gastroenterology’s 2025 Crohn’s disease guidelines introduce key advancements in personalized care, diagnostics, and treatment. Highlights include genetic testing to guide therapy, adoption of intestinal ultrasound for non-invasive monitoring, and the inclusion of new biologics. Emphasizing shared decision-making and holistic care, the guidelines aim to improve outcomes by tailoring strategies to each patient’s unique profile and preferences.
In this Future Leaders interview, Dr Salvatore Oliva discusses his path to paediatric gastroenterology, highlighting his focus on chronic inflammatory conditions like IBD and EGIDs. He shares insights on leading European collaborative research, the integration of innovation into clinical care, and the promise of precision medicine. Dr Oliva also offers guidance for early-career doctors drawn to this dynamic and multidisciplinary field.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
